SiRNA inhibiting toxoplasma gondii wx2 gene expression and use thereof

Abstract

The invention particularly relates to a siRNA for restaining the TOX wx 2 gene expression and an application of the siRNA to the screening of the TOX attenuated virus or toxicity-decreasing living vaccine. A pair of 60 ribonucleotide barrette-shaped DNA respectively containing 9 basic group palindrome structures is designed according to the 895 to 913 position sequence of the TOX wx 2 gene (the accession number of GenBank is AY238892). The barrette-shaped DNA is adopted to produce interfering particles which are guided into the TOX body by the electroporation method to obtain the RNA interfering TOX strain wx 2b-I capable of expressing the siRNA continuously in the TOX body, the animal infection experiment shows that the toxicity of the TOX is reduced evidently; the surviving time of a mouse with the toxicity is evidently longer than the negative control and wild type TOX strain; the attenuated virus or toxicity-decreasing living vaccine used for the cattle and pets are hopeful to be explored.

Description

technical field [0001] The invention relates to an siRNA, in particular to an siRNA inhibiting the expression of the toxoplasma wx2 gene and its application in screening live attenuated vaccines of the toxoplasma gondii. Background technique [0002] Toxoplasma gondii is an obligate intracellular parasitic opportunistic protozoa with a complex life cycle and many tissues and organs involved. Toxoplasma gondii infection in pregnant women can cause miscarriage, premature birth, teratogenicity, stillbirth, congenital toxoplasmosis in infants and young children, mental retardation in children, etc., which has a serious impact on population quality and prenatal care. In recent years, with the rise of pet fever, the opportunities for human-animal contact have increased, which has brought new problems to the prevalence of toxoplasmosis. Toxoplasma encephalitis has become one of the leading causes of death in AIDS patients, as well as one of the leading causes of death and psychiat...

AI Technical Summary

Problems solved by technology

[0003] At present, there is no very ideal drug for the treatment of toxoplasmosis. The existing chemical drugs have defects such as long treatment cycle, large drug side effects, and inability to cure them. So far, there is no drug that can kill the parasites in the cyst. In addition, the superinfection of Toxoplasma gondii is very rapid, so it has not been well contained despite various efforts

Images